Skip to content
lsd.com
CompletedEarly Phase 1

Mood Effects of Serotonin Agonists: Depression

NCT07017478 · MESA-D · University of Chicago

Closed to entry
Status
Not accepting participants
Early Phase 1
Phase
41
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Acute Mood Measures

    Measured over Peak change (~2 hours post-drug) from pre-drug baseline

  • Acute Mood Measures

    Measured over Peak change (~2 hours post-drug) from pre-drug baseline

  • Delayed Mood Measures

    Measured over Change from baseline (orientation) to 48-hour followup

  • Effort expenditure for reward (EEFRT) Behavioral Task Performance

    Measured over 2 hours post-drug administration

  • Sleep Quality

    Measured over Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug

  • Sleep Quality

    Measured over Change from baseline (pre-drug) to Night 0, 1, and 2 post-drug

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 40 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * English Fluency * high school education or higher * BMI between 19-30 kg/m2 Exclusion Criteria: * individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease) * high blood pressure (\>140/90) * current suicidal ideation or suicide attempt in past 12 months * past year severe substance use disorder * personal or first-degree relative with history of psychosis * currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks) * active panic disorder * severe obsessive-compulsive disorder * severe post-traumatic stress disorder * women who are pregnant or planning to become pregnant

Where

1 study site

FacilityCityRegionCountry
University of ChicagoChicagoIllinoisUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07017478 on ClinicalTrials.gov →

Last updated in the registry 2026-07-10. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in

All 12 trials from University of Chicago →